Casi pharmaceuticals announces plan to submit ind application for cid-103, an anti-cd 38 antibody in antibody-mediated rejection, and receipt of a non-binding proposal to acquire entire china business of the company

Beijing , june 26, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi) ("casi" or the "company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the company is planning to submit an investigational new drug ("ind") application to the u.s. food and drug administration ("fda") for cid-103 for the treatment of antibody-mediated rejection ("amr") in kidney transplant recipients by the end of 2024. cid-103 is a fully human igg1 anti-cd38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other anti-cd38 monoclonal antibodies.
CASI Ratings Summary
CASI Quant Ranking